Target intelligence / Profile preview

Synaptic vesicle release machinery

Molecular classification
Other (molecular machine; supercomplex), Composed of: SNARE proteins (Syntaxin-1, Synaptobrevin/VAMP2, SNAP-25), regulatory proteins (Synaptotagmin-1, Complexin, Munc13, Munc18), synaptic vesicle proteins (Synaptophysin)
01

Overview

The synaptic vesicle release machinery comprises a network of interacting proteins that regulate all steps of neurotransmitter exocytosis at presynaptic nerve terminals. The central component is the SNARE complex, consisting of Syntaxin-1, Synaptobrevin (VAMP2), and SNAP-25, which drives membrane fusion between synaptic vesicles and the presynaptic membrane. This process is tightly regulated by proteins such as Synaptotagmin-1 (the calcium sensor for fast release), Complexin (fusion clamp/activator), Munc13 (priming factor), Munc18 (SNARE chaperone), and Synaptophysin (vesicle trafficking regulator)[1][3][4][5][6][8]. Disruption in the function or balance of these proteins leads to severe defects in synaptic transmission and is implicated in multiple neurological and psychiatric disorders[5]. The machinery is a target for bacterial neurotoxins but not for approved therapeutics.

Other names
Synaptic fusion machinerySNARE complex and associated proteinsNeurotransmitter release machinery
02

Mechanism of action

Proteolytic cleavage of SNARE proteins (e.g., botulinum and tetanus toxins inhibit vesicular fusion by cleaving SNAREs) Inhibition of SNARE complex assembly and exocytosis

03

Biological functions

Neurotransmitter releaseSynaptic transmissionMembrane fusionSynaptic vesicle docking and primingCalcium-triggered exocytosis
04

Disease associations

Neurodegenerative disease (e.g., defects linked to Alzheimer’s, Parkinson’s)Epilepsy (mutations cause synaptic transmission deficits)Depression, psychiatric disordersNeurodevelopmental disorders
05

Safety considerations

Disruption of machinery results in broad impairment of synaptic transmission, linked to paralysis, cognitive deficits, seizures, or neurodegenerationOff-target inhibition causes widespread nervous system toxicity
06

Interacting drugs

Botulinum toxin (targets SNAREs)

1 more in the full profile.

Beyond the preview

Go deeper on Synaptic vesicle release machinery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptic vesicle release machinery.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call